Skip to content
Open access

CD25-based graft-versus-host disease prophylaxis after haploidentical hematopoietic stem cell transplantation: comparison of two prophylactic strategies.

Oct 2026 · Haematologica · 0 citations
Medicine

TL;DR

It is suggested that a higher-dose anti-CD25, methotrexate-free prophylactic approach may reduce acute GVHD and improve GRFS after haplo-HSCT, while its effects on long-term disease control and survival require confirmation in multicenter randomized trials.

Abstract

Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is widely used for hematologic malignancies, yet balancing graft-versus-host disease (GVHD) prophylaxis and immune reconstitution remains challenging. In this prospective, nonrandomized study, we compared a higher-dose anti-CD25 strategy that omitted methotrexate with a conventional lower-dose anti-CD25 regimen that included methotrexate. Lower cumulative anti-thymocyte globulin exposure was observed in the higher-dose group. From May 2022 to January 2025, 276 patients were enrolled (lower-dose group, n=149; higher-dose group, n=127). After a median follow-up of 28.4 months, the higher-dose strategy was associated with a lower 100-day cumulative incidence of grade III-IV acute GVHD (7.9% vs. 17.5%; adjusted subdistribution hazard ratio, 0.39; 95% confidence interval, 0.18-0.88; p=0.022) and improved graft-versus-host diseasefree, relapse-free survival (GRFS) (adjusted hazard ratio, 0.59; 95% confidence interval, 0.43-0.83; p=0.002). Chronic GVHD, overall survival, disease-free survival, relapse, and non-relapse mortality did not differ significantly between groups. Exploratory immune monitoring showed transiently lower CD4+ T-cell counts at day +30 in the higherdose group, whereas longitudinal immune reconstitution trajectories and infectious complications were broadly comparable. These findings suggest that a higher-dose anti-CD25, methotrexate-free prophylactic approach may reduce acute GVHD and improve GRFS after haplo-HSCT, while its effects on long-term disease control and survival require confirmation in multicenter randomized trials. Trial registration: Chinese Clinical Trial Registry, ChiCTR2200060184.

Read PDF

Similar papers

Review Open access Oct 2026

Abatacept for Prophylaxis of Acute and Chronic Graft-Versus-Host-Disease in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis of Cohort Studies.

BACKGROUND Graft-versus-host disease (GvHD) remains one of the most significant complications of hematopoietic stem cell transplantation (HSCT). Abatacept, a selective T-cell costimulation modulator, is a relatively novel prophylactic agent, though pediatric data remain limited. PROCEDURE A systematic review and meta...

M. Kruizinga, Anne B. Verbeek, C. Lindemans et al. · 0 citations
Open access Oct 2026

Allogeneic anti-CD19 CAR-T therapy demonstrates sustained efficacy and manageable safety in post-allo-HSCT relapsed B-ALL with extramedullary disease

Relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem-cell transplantation (allo-HSCT), particularly with extramedullary disease (EMD), has a dismal prognosis. The efficacy and durability of allogeneic chimeric antigen receptor T cell (allo-CAR-T) therapy in this setting remain...

Rui Liu, Jian Zhang, Ying Li et al. · 0 citations
Open access Sep 2026

Reduced-intensity post-cyclophosphamide-based graft-versus-host disease prophylaxis for umbilical cord blood transplantation: a single-center pilot study

Background Post-cyclophosphamide (PTCy)-based GVHD prophylaxis has shown significant success in haploidentical transplants. The potential of PTCy in adult umbilical blood transplantation (UCBT) remains unclear due to concerns about engraftment, given the limited number of CD34+ cells. This study aimed to explore the pr...

Yun-Tian Ding, Wei Xiao, Ya-Qun Wang et al. · 0 citations
Open access Sep 2026

GVHD prophylaxis and incidence in contemporary alloHSCT: a large real-world GETH/TC analysis.

Graft-versus-host disease (GVHD) remains a major limitation of allogeneic hematopoietic stem cell transplantation (alloHSCT) outcomes. The increasing use of post-transplant cyclophosphamide (PTCy) and antithymocyte globulin (ATG) has expanded beyond haploidentical transplantation to matched related (MRD) and unrelated...

C. Martínez, L. Bento, M. Salas et al. · 0 citations
Open access Sep 2026

Vorinostat for graft-versus-host disease prevention in pediatric and young adult patients with hematologic malignancies.

BACKGROUND This prospective, single-arm, multicenter phase 1/2 trial evaluated vorinostat added to standard graft-versus-host disease (GVHD) prophylaxis in pediatric, adolescent, and young adult (AYA) patients undergoing allogeneic hematopoietic cell transplantation (HCT) from HLA-matched related, HLA-matched unrelated...

Nicolas Parnell, Xiao Cao, J. H. Beumer et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.